Severe pulmonary arterial hypertension (PAH) is rarely observed as the initial manifestation of systemic lupus erythematosus (SLE), and the diagnosis is often delayed. Here we present the case of a 32-year-old woman with severe PAH as the initial manifestation of SLE, who was successfully treated with mycophenolate mofetil and cyclosporine. This case offered the opportunity to critically review the epidemiology data, predictive markers, and pathogenic pathways of SLE-associated PAH (SLE-PAH) in relation to the currently available therapeutic options and to the main clinical trials of the last 10 years focused on the treatment of SLE-PAH. Mycophenolate mofetil and cyclosporine - currently used in the maintenance phase of the disease in certain clinical settings - should be considered, as an alternative to cyclophosphamide, in future clinical trials aimed at evaluating the most effective treatment of SLE-PAH at presentation.

Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature / Prete, M., Fatone, M.C., Vacca, A., Racanelli, V., Perosa, F.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 32:2(2014), pp. 267-274.

Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature

RACANELLI, Vito;
2014-01-01

Abstract

Severe pulmonary arterial hypertension (PAH) is rarely observed as the initial manifestation of systemic lupus erythematosus (SLE), and the diagnosis is often delayed. Here we present the case of a 32-year-old woman with severe PAH as the initial manifestation of SLE, who was successfully treated with mycophenolate mofetil and cyclosporine. This case offered the opportunity to critically review the epidemiology data, predictive markers, and pathogenic pathways of SLE-associated PAH (SLE-PAH) in relation to the currently available therapeutic options and to the main clinical trials of the last 10 years focused on the treatment of SLE-PAH. Mycophenolate mofetil and cyclosporine - currently used in the maintenance phase of the disease in certain clinical settings - should be considered, as an alternative to cyclophosphamide, in future clinical trials aimed at evaluating the most effective treatment of SLE-PAH at presentation.
2014
2
Prete, Marcella; Fatone, Maria Celeste; Vacca, Angelo; Racanelli, Vito; Perosa, Federico
Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature / Prete, M., Fatone, M.C., Vacca, A., Racanelli, V., Perosa, F.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 32:2(2014), pp. 267-274.
File in questo prodotto:
File Dimensione Formato  
69 PAH as SLE onset clin exp rheumatol.pdf

Solo gestori archivio

Descrizione: online first
Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 745.14 kB
Formato Adobe PDF
745.14 kB Adobe PDF   Visualizza/Apri
article (4).pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 758.31 kB
Formato Adobe PDF
758.31 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/387287
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
  • OpenAlex ND
social impact